A dose-dependent beneficial effect of methotrexate on the risk of interstitial lung disease in rheumatoid arthritis patients.

Autor: Kur-Zalewska J; Department of Internal Diseases and Rheumatology, Military Institute of Medicine, Warsaw, Poland.; Clinical Research Support Center, Military Institute of Medicine, Warsaw, Poland., Kisiel B; Department of Internal Diseases and Rheumatology, Military Institute of Medicine, Warsaw, Poland.; Clinical Research Support Center, Military Institute of Medicine, Warsaw, Poland., Kania-Pudło M; Department of Radiology, Military Institute of Medicine, Warsaw, Poland., Tłustochowicz M; Department of Internal Diseases and Rheumatology, Military Institute of Medicine, Warsaw, Poland., Chciałowski A; Department of Infectious Diseases and Allergology, Military Institute of Medicine, Warsaw, Poland., Tłustochowicz W; Department of Internal Diseases and Rheumatology, Military Institute of Medicine, Warsaw, Poland.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2021 Apr 16; Vol. 16 (4), pp. e0250339. Date of Electronic Publication: 2021 Apr 16 (Print Publication: 2021).
DOI: 10.1371/journal.pone.0250339
Abstrakt: Objectives: The aim of the study was to assess the influence of different factors, including treatment, on the risk of ILD in the course of RA.
Methods: A total of 109 RA patients were included in the analysis. High-resolution computed tomography (HRCT) of chest was obtained in each patient. Patients were classified as having ILD (ILD group) or not (N-ILD group). The ILD was graded using the semi-quantitative Warrick scale of fibrosis. Warrick extent score (WES) and Warrick severity score (WSS) were calculated separately for each patient, then combined to obtain a global score (WGS).
Results: In univariate analysis the presence of ILD was associated positively with age (P = 5x10-6) and negatively with MTX treatment (P = 0.0013), mean MTX dose per year of treatment (P = 0.003) and number of DMARDs used (P = 0.046). On multivariate analysis only age and treatment with MTX were independently associated with the presence of ILD. WGS was significantly lower in patients treated with MTX in a dose of ≥15 mg/week (MTX≥15 group) as compared to patients treated with lower doses of MTX (0Consclusions: We found a beneficial effect of MTX on RA-ILD. Importantly, this effect seems to be dose dependent.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje